BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35020170)

  • 21. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
    Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
    J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial.
    Moeremans K; Annemans L
    Int J Gynecol Cancer; 2006; 16 Suppl 2():576-8. PubMed ID: 17010076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
    Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
    Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluorouracil plasma monitoring: systematic review and economic evaluation of the My5-FU assay for guiding dose adjustment in patients receiving fluorouracil chemotherapy by continuous infusion.
    Freeman K; Connock M; Cummins E; Gurung T; Taylor-Phillips S; Court R; Saunders M; Clarke A; Sutcliffe P
    Health Technol Assess; 2015 Nov; 19(91):1-321, v-vi. PubMed ID: 26542268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study.
    McCowan C; Wang S; Thompson AM; Makubate B; Petrie DJ
    Br J Cancer; 2013 Sep; 109(5):1172-80. PubMed ID: 23949153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness analysis of extended adjuvant endocrine therapy in the treatment of post-menopausal women with hormone receptor positive breast cancer.
    Erman A; Nugent A; Amir E; Coyte PC
    Breast Cancer Res Treat; 2014 Jun; 145(2):267-79. PubMed ID: 24771048
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China.
    Wei X; Sun H; Zhuang J; Weng X; Zheng B; Lin Q; Zhang G; Cai J
    Clin Drug Investig; 2020 Jan; 40(1):25-32. PubMed ID: 31559573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole.
    Skedgel C; Rayson D; Dewar R; Younis T
    Breast Cancer Res Treat; 2007 Mar; 101(3):325-33. PubMed ID: 16897433
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients.
    Ten Ham RMT; van Nuland M; Vreman RA; de Graaf LG; Rosing H; Bergman AM; Huitema ADR; Beijnen JH; Hövels AM
    Value Health; 2021 Jan; 24(1):121-128. PubMed ID: 33431146
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients.
    Klopp-Schulze L; Joerger M; Wicha SG; Ter Heine R; Csajka C; Parra-Guillen ZP; Kloft C
    Clin Pharmacokinet; 2018 Feb; 57(2):229-242. PubMed ID: 28540639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer.
    Risebrough NA; Verma S; Trudeau M; Mittmann N
    Cancer; 2007 Aug; 110(3):499-508. PubMed ID: 17592825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
    Dunn C; Keam SJ
    Pharmacoeconomics; 2006; 24(5):495-517. PubMed ID: 16706574
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic Evaluation of Letrozole for Early Breast Cancer in a Health Resource-Limited Setting.
    Ye M; Lu J; Yang F; Wu B
    Biomed Res Int; 2018; 2018():9282646. PubMed ID: 30155484
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proactive therapeutic drug monitoring of adalimumab for pediatric Crohn's disease patients: A cost-effectiveness analysis.
    Yao J; Jiang X; You JHS
    J Gastroenterol Hepatol; 2021 Sep; 36(9):2397-2407. PubMed ID: 33326123
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer.
    Stenehjem DD; Bellows BK; Yager KM; Jones J; Kaldate R; Siebert U; Brixner DI
    Oncologist; 2016 Feb; 21(2):196-204. PubMed ID: 26614710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer.
    El Ouagari K; Karnon J; Delea T; Talbot W; Brandman J
    Breast Cancer Res Treat; 2007 Jan; 101(1):37-49. PubMed ID: 16821085
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
    Liberato NL; Marchetti M; Barosi G
    J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States.
    Qi CZ; Bollu V; Yang H; Dalal A; Zhang S; Zhang J
    Clin Ther; 2021 Aug; 43(8):1300-1319.e8. PubMed ID: 34380609
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cancer Care Coordinators to Improve Tamoxifen Persistence in Breast Cancer: How Heterogeneity in Baseline Prognosis Impacts on Cost-Effectiveness.
    Nair N; Kvizhinadze G; Blakely T
    Value Health; 2016 Dec; 19(8):936-944. PubMed ID: 27987643
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)-Positive Breast Cancer.
    Kunst N; Wang SY; Hood A; Mougalian SS; DiGiovanna MP; Adelson K; Pusztai L
    JAMA Netw Open; 2020 Nov; 3(11):e2027074. PubMed ID: 33226431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.